TGTX Stock Summary and Trading Ideas (TG Therapeutics | NASDAQ:TGTX)

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics trades on the NASDAQ stock market under the symbol TGTX.

As of January 16, 2026, TGTX stock price declined to $30.57 with 2,395,580 million shares trading.

TGTX has a beta of 0.20, meaning it tends to be less sensitive to market movements. TGTX has a correlation of 0.00 to the broad based SPY ETF.

TGTX has a market cap of $4.85 billion. This is considered a Mid Cap stock.

Last quarter TG Therapeutics reported $162 million in Revenue and $2.43 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $2.21.

In the last 3 years, TGTX traded as high as $46.48 and as low as $6.46.

The top ETF exchange traded funds that TGTX belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.

TGTX has underperformed the market in the last year with a return of +4.9%, while the SPY ETF gained +18.1%. In the last 3 month period, TGTX fell short of the market, returning -12.3%, while SPY returned +5.0%. However, in the most recent 2 weeks TGTX has outperformed the stock market by returning +4.4%, while SPY returned +1.2%.

TGTX support price is $29.68 and resistance is $31.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TGTX shares will trade within this expected range on the day.